Скачать с ютуб Light Adjustable Lens LAL в хорошем качестве

Light Adjustable Lens LAL

Dr. Youssef and Premium Vision Surgical Centres are proud to announce the availability of Light Adjustable Lens™ (LAL) from RxSight® which is the first and only FDA-approved intraocular lens (IOL) that can be adjusted postoperatively to improve uncorrected visual acuity. The LAL is made of a special photosensitive material that can be reshaped in response to ultraviolet light. First, routine cataract surgery is performed and the LAL is implanted. Then, 2 to 3 weeks after surgery, a proprietary Light Delivery Device (LDD) is used to adjust the lens based on the manifest refraction. Each light treatment takes approximately 90 seconds and, unlike with standard IOLs, patients are able to test vision options and provide direct input into their refractive correction during their LDD treatments. In a clinical study (N = 600), patients who received the LAL were twice as likely to achieve 20/20 vision at 6 months without glasses as those who received a standard monofocal IOL. And for your patients who would like to reduce their dependence on near correction, precise mini-monovision can be achieved with the LDD. This vision option can be experienced by the patient to see how it works in their daily activities; if they ultimately prefer to modify the visual correction in both eyes, this change can be performed with their next LDD treatment. Once the patient achieves vision that matches their goals and expectations, the final light treatment is performed to permanently lock in their IOL power. The LAL offers tremendous advantages over all IOLs currently available. The lens is an ideal option for patients who have previously undergone any type of refractive surgery, which makes accurate preoperative measurements more difficult and significantly increases the chance of a postoperative refractive surprise. The LAL also offers patients the opportunity to try monovision or mini-monovision and to achieve their best possible vision. The results from clinical trials with the LAL show LASIK-like outcomes, with many patients obtaining 20/15 vision. We are excited to share the LAL with your patients and look forward to exceeding their expectations with this state-of-the-art, game-changing technology. For more information about the LAL for you and your patients, please visit RxSight.com.